中剂量阿糖胞苷对急性髓系白血病M2的疗效分析

目的:观察中剂量阿糖胞苷(ID-Ara-C)在急性髓性白血病(AML)M2缓解后巩固强化治疗中的疗效。方法:AML-M2在诱导缓解后,先予两个标准剂量巩固治疗,之后采用ID-Ara-C强化治疗,分别观察t(8;21)患者组与正常核型组的复发率、无病生存率以及总生存率。结果:t(8;21)患者组复发率为46.1%,低于正常核型组的复发率(61.9%);5年无病生存率为53.9%,高于正常核型组的38.0%,两组数据差异有显著性意义(P<0.05)。结论:对于AML-M2患者在第1次诱导缓解治疗后,应用4个周期含ID-Ara-C方案进行个体化巩固强化治疗,可以降低复发率,减少治疗相关死亡率。

The individualized treatment to acute myeloid leukemia (M2) patients with intermediate-dose cytarabine

Objective: To observe the effect of Intermediate-dose cytarabine(ID-Ara-C) in acute myeloid leukemia(AML)M2 intensive treatment after remission.Methods: AML-M2 in the induction of remission,be thoroughly two standard dose consolidation therapy,followed by ID-Ara-C intensification therapy,were observed in t(8;21) in patients with normal karyotype group and the relapse rate,disease-free survival and overall survival.Results: The recurrence rate of t(8;21) patients was 46.1%,lower than the normal karyotype of the relapse rate(61.9%).5-year disease-free survival rate was 53.9%,higher than 38.0% of nuclear-based group,two groups data,significant differences(P<0.05).Conclusion: After the 1st remission induction of AML-M2 patients,the application of four cycles with ID-Ara-C program to consolidate individual intensive treatment can reduce the recurrence rate,reducing treatment-related mortality.